These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

207 related articles for article (PubMed ID: 30534046)

  • 21. Redox reactions of neurotransmitters possibly involved in the progression of Parkinson's Disease.
    Linert W; Jameson GN
    J Inorg Biochem; 2000 Apr; 79(1-4):319-26. PubMed ID: 10830883
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Dopamine, 6-hydroxydopamine, iron, and dioxygen--their mutual interactions and possible implication in the development of Parkinson's disease.
    Linert W; Herlinger E; Jameson RF; Kienzl E; Jellinger K; Youdim MB
    Biochim Biophys Acta; 1996 Aug; 1316(3):160-8. PubMed ID: 8781534
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Dopamine complexes of iron in the etiology and pathogenesis of Parkinson's disease.
    Arreguin S; Nelson P; Padway S; Shirazi M; Pierpont C
    J Inorg Biochem; 2009 Jan; 103(1):87-93. PubMed ID: 18976814
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Altered mitochondrial function, iron metabolism and glutathione levels in Parkinson's disease.
    Jenner P
    Acta Neurol Scand Suppl; 1993; 146():6-13. PubMed ID: 8333254
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Domain homologues of dopamine beta-hydroxylase and ferric reductase: roles for iron metabolism in neurodegenerative disorders?
    Ponting CP
    Hum Mol Genet; 2001 Aug; 10(17):1853-8. PubMed ID: 11532994
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Clues to the mechanism underlying dopamine cell death in Parkinson's disease.
    Jenner P
    J Neurol Neurosurg Psychiatry; 1989 Jun; Suppl(Suppl):22-8. PubMed ID: 2666576
    [TBL] [Abstract][Full Text] [Related]  

  • 27. The role of transition metals in the pathogenesis of Parkinson's disease.
    Kienzl E; Puchinger L; Jellinger K; Linert W; Stachelberger H; Jameson RF
    J Neurol Sci; 1995 Dec; 134 Suppl():69-78. PubMed ID: 8847547
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Ironing iron out in Parkinson's disease and other neurodegenerative diseases with iron chelators: a lesson from 6-hydroxydopamine and iron chelators, desferal and VK-28.
    Youdim MB; Stephenson G; Ben Shachar D
    Ann N Y Acad Sci; 2004 Mar; 1012():306-25. PubMed ID: 15105275
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Dopamine, Oxidative Stress and Protein-Quinone Modifications in Parkinson's and Other Neurodegenerative Diseases.
    Monzani E; Nicolis S; Dell'Acqua S; Capucciati A; Bacchella C; Zucca FA; Mosharov EV; Sulzer D; Zecca L; Casella L
    Angew Chem Int Ed Engl; 2019 May; 58(20):6512-6527. PubMed ID: 30536578
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Cytotoxic and genotoxic potential of dopamine.
    Stokes AH; Hastings TG; Vrana KE
    J Neurosci Res; 1999 Mar; 55(6):659-65. PubMed ID: 10220107
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Novel Alpha-Synuclein Oligomers Formed with the Aminochrome-Glutathione Conjugate Are Not Neurotoxic.
    Huenchuguala S; Sjödin B; Mannervik B; Segura-Aguilar J
    Neurotox Res; 2019 Feb; 35(2):432-440. PubMed ID: 30343424
    [TBL] [Abstract][Full Text] [Related]  

  • 32. In cellulo monitoring of quinone reductase activity and reactive oxygen species production during the redox cycling of 1,2 and 1,4 quinones.
    Cassagnes LE; Perio P; Ferry G; Moulharat N; Antoine M; Gayon R; Boutin JA; Nepveu F; Reybier K
    Free Radic Biol Med; 2015 Dec; 89():126-34. PubMed ID: 26386287
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Hesperidin attenuates iron-induced oxidative damage and dopamine depletion in Drosophila melanogaster model of Parkinson's disease.
    Poetini MR; Araujo SM; Trindade de Paula M; Bortolotto VC; Meichtry LB; Polet de Almeida F; Jesse CR; Kunz SN; Prigol M
    Chem Biol Interact; 2018 Jan; 279():177-186. PubMed ID: 29191452
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Neuromelanin associated redox-active iron is increased in the substantia nigra of patients with Parkinson's disease.
    Faucheux BA; Martin ME; Beaumont C; Hauw JJ; Agid Y; Hirsch EC
    J Neurochem; 2003 Sep; 86(5):1142-8. PubMed ID: 12911622
    [TBL] [Abstract][Full Text] [Related]  

  • 35. The Therapeutic Implications of Tea Polyphenols Against Dopamine (DA) Neuron Degeneration in Parkinson's Disease (PD).
    Zhou ZD; Xie SP; Saw WT; Ho PGH; Wang H; Lei Z; Yi Z; Tan EK
    Cells; 2019 Aug; 8(8):. PubMed ID: 31426448
    [No Abstract]   [Full Text] [Related]  

  • 36. NADPH- and NADH-dependent oxygen radical generation by rat liver nuclei in the presence of redox cycling agents and iron.
    Kukiełka E; Cederbaum AI
    Arch Biochem Biophys; 1990 Dec; 283(2):326-33. PubMed ID: 2275546
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Tyrosine hydroxylase is inactivated by catechol-quinones and converted to a redox-cycling quinoprotein: possible relevance to Parkinson's disease.
    Kuhn DM; Arthur RE; Thomas DM; Elferink LA
    J Neurochem; 1999 Sep; 73(3):1309-17. PubMed ID: 10461926
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Redox- and non-redox-metal-induced formation of free radicals and their role in human disease.
    Valko M; Jomova K; Rhodes CJ; Kuča K; Musílek K
    Arch Toxicol; 2016 Jan; 90(1):1-37. PubMed ID: 26343967
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Are dopamine derivatives implicated in the pathogenesis of Parkinson's disease?
    Bisaglia M; Filograna R; Beltramini M; Bubacco L
    Ageing Res Rev; 2014 Jan; 13():107-14. PubMed ID: 24389159
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Oxidative mechanisms in nigral cell death in Parkinson's disease.
    Jenner P
    Mov Disord; 1998; 13 Suppl 1():24-34. PubMed ID: 9613715
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.